Journal of Experimental Medicine Impact Factor

Among Immunology journals, Journal of Experimental Medicine ranks in the top 7% by impact factor (JCR 2024). This ranking is based on our analysis of 20,449 journals in the Clarivate JCR 2024 database.

The 10.6 JIF places JEM solidly in the upper tier of immunology and disease biology. The five-year JIF (13.5) running well above the two-year figure tells you that JEM papers keep accumulating citations long after publication. This is the profile of a journal that publishes work with lasting reference value.

JEM's cited half-life of 14.2 years is one of the longest in immunology, second only to a few review journals. Papers published here a decade ago are still being cited regularly. That's a signal of enduring scientific quality, and it's one reason JEM's community reputation exceeds what the current two-year JIF might suggest.

The journal publishes about 148 citable items per year. That's relatively low volume, which means each paper gets strong editorial attention and community visibility. JEM isn't a high-throughput venue; it's a selective journal where the editorial team takes the review process seriously and invests in published papers.

JEM saw a pandemic-era spike driven by heavily cited immunology and disease biology papers from 2020-2021. The return to 10.6 in 2024 represents the journal's structural baseline. The five-year JIF of 13.5 confirms strong long-tail citation performance.

• whether the mechanistic depth is sufficient for Rockefeller University Press standards
• how JEM compares to Immunity for your specific subfield
• how long the review process will take (JEM reviews are thorough)
• whether the disease biology angle is strong enough for this venue
• how your specific paper will perform relative to the journal average

In our pre-submission review work on manuscripts targeting Journal of Experimental Medicine, three patterns account for most of the desk rejections we see.

Immunology papers without disease connection. JEM has a distinctive editorial identity: it sits at the intersection of immunology and experimental medicine, not purely within immunology as a field. We see manuscripts from strong immunology labs that generate rigorous mechanistic data on immune cell biology but do not connect that mechanism to a disease process, pathological state, or clinical question. Those papers are well-suited for Immunity or Journal of Immunology, depending on depth, but they do not fit JEM's editorial mission. The journal's century-long tradition of "experimental medicine" is literal, the work should be medicine-relevant, not just immunology-relevant.

Strong phenotype papers without mechanism. JEM maintains high methodological standards consistent with Rockefeller University Press's reputation. We regularly see papers that describe a compelling phenotype, an immune subset expands in disease, a cytokine drives pathology, a genetic variant correlates with outcome, but do not have the mechanistic follow-through to explain the causal chain. At this journal's editorial bar, correlation and phenotype are the starting point, not the conclusion. Reviewers will push for mechanistic explanation, and manuscripts that cannot deliver it usually face rejection or requests for additional experiments that may be impractical.

Papers too narrow for JEM's broad experimental medicine scope. JEM is not a subspecialty journal. It covers the full breadth of experimental medicine, from cancer immunology and infectious disease to autoinflammation and vascular biology. Papers that are highly specialized within one narrow niche, a specific cytokine signaling node in one disease context without broader implication, can find the editorial fit difficult even if the science is excellent. The journal works best for papers where the disease biology implication is recognizable to readers across the experimental medicine spectrum, not just to specialists in one subfield.

JEM editors want mechanistic work in disease biology, immunology, and pathology. The editorial bar is:

• clear mechanistic insight, not just correlation or phenotypic observation
• disease relevance that goes beyond the immune system alone
• experimental rigor consistent with Rockefeller University Press standards
• work that matters to both immunologists and disease biologists

JEM has also expanded into areas like cancer immunology, infectious disease immunology, and autoinflammatory disease. Papers that sit at the intersection of immunity and human disease have a strong track record here.

The journal's editorial approach is notably author-friendly compared to Cell Press and Nature Portfolio. Review processes tend to be constructive, and the editorial team has a reputation for giving useful guidance rather than just rendering verdicts.

Submit if:

• the paper has strong mechanistic insight in disease biology or immunology
• the work bridges immune mechanism and disease biology
• the manuscript is too disease-focused for Immunity but too strong for Journal of Immunology
• you value JEM's constructive editorial process and Rockefeller University Press tradition

Think twice if:

• Immunity or Nature Immunology is a realistic target
• the work is primarily clinical without mechanistic depth
• the audience is narrower than JEM's broad experimental medicine readership
• the paper would benefit from Cell Press or Nature Portfolio branding

JEM's two-year and five-year pattern matters because the journal behaves like a durable reference venue, not a citation-spike journal. A five-year JIF well above the two-year figure tells you the papers often compound in value as disease biology and immunology communities keep building on them.

The real use of this page is to help authors decide whether their manuscript belongs in JEM's bridge zone: mechanistic work with clear disease consequence, but not necessarily the exact editorial profile of Immunity or Nature Immunology. That bridge identity is why JEM still matters far beyond its headline metric.

• It helps when the paper genuinely connects immune mechanism and disease biology.
• It helps when you are choosing between JEM, Immunity, Nature Immunology, and broader disease-oriented journals.
• It misleads when the manuscript is mainly clinical without enough mechanism.
• It misleads when the paper is mainly immunology and the disease framing is too thin to justify JEM's identity.

JEM remains appealing because the journal combines Rockefeller University Press credibility, low volume, strong staying power, and a more constructive editorial reputation than some higher-metric venues. For the right paper, that combination can matter more than chasing the biggest possible JIF.

• Immunity impact factor
• Nature Immunology impact factor
• Journal of Immunology impact factor

The impact factor for Journal of Experimental Medicine measures average citations per paper over 2 years. It does not measure the quality of any individual paper, the prestige within a specific subfield, or whether the journal is the right fit for your work. A high IF does not guarantee your paper will be cited, and a lower IF does not mean the journal lacks influence in its specialty.

Impact factors also do not account for field-specific citation patterns. Journals in clinical medicine accumulate citations faster than journals in mathematics or ecology. Comparing IFs across fields is misleading.

Before submitting, a JEM submission readiness check can assess whether your manuscript fits the journal's actual editorial scope and mechanistic evidence bar.